Literature DB >> 32432715

mmCSM-AB: guiding rational antibody engineering through multiple point mutations.

Yoochan Myung1,2, Douglas E V Pires1,2,3, David B Ascher1,2,4.   

Abstract

While antibodies are becoming an increasingly important therapeutic class, especially in personalized medicine, their development and optimization has been largely through experimental exploration. While there have been many efforts to develop computational tools to guide rational antibody engineering, most approaches are of limited accuracy when applied to antibody design, and have largely been limited to analysing a single point mutation at a time. To overcome this gap, we have curated a dataset of 242 experimentally determined changes in binding affinity upon multiple point mutations in antibody-target complexes (89 increasing and 153 decreasing binding affinity). Here, we have shown that by using our graph-based signatures and atomic interaction information, we can accurately analyse the consequence of multi-point mutations on antigen binding affinity. Our approach outperformed other available tools across cross-validation and two independent blind tests, achieving Pearson's correlations of up to 0.95. We have implemented our new approach, mmCSM-AB, as a web-server that can help guide the process of affinity maturation in antibody design. mmCSM-AB is freely available at http://biosig.unimelb.edu.au/mmcsm_ab/.
© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Year:  2020        PMID: 32432715      PMCID: PMC7319589          DOI: 10.1093/nar/gkaa389

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  59 in total

1.  PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration.

Authors:  Linda J Chan; Jürgen B Bulitta; David B Ascher; John M Haynes; Victoria M McLeod; Christopher J H Porter; Charlotte C Williams; Lisa M Kaminskas
Journal:  Mol Pharm       Date:  2015-02-18       Impact factor: 4.939

2.  Antibody interface prediction with 3D Zernike descriptors and SVM.

Authors:  Sebastian Daberdaku; Carlo Ferrari
Journal:  Bioinformatics       Date:  2019-06-01       Impact factor: 6.937

3.  mCSM-AB2: guiding rational antibody design using graph-based signatures.

Authors:  Yoochan Myung; Carlos H M Rodrigues; David B Ascher; Douglas E V Pires
Journal:  Bioinformatics       Date:  2020-03-01       Impact factor: 6.937

4.  Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features.

Authors:  W Kabsch; C Sander
Journal:  Biopolymers       Date:  1983-12       Impact factor: 2.505

5.  Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on 'black bone disease' in Italy.

Authors:  Martina Nemethova; Jan Radvanszky; Ludevit Kadasi; David B Ascher; Douglas E V Pires; Tom L Blundell; Berardino Porfirio; Alessandro Mannoni; Annalisa Santucci; Lia Milucci; Silvia Sestini; Gianfranco Biolcati; Fiammetta Sorge; Caterina Aurizi; Robert Aquaron; Mohammed Alsbou; Charles Marques Lourenço; Kanakasabapathi Ramadevi; Lakshminarayan R Ranganath; James A Gallagher; Christa van Kan; Anthony K Hall; Birgitta Olsson; Nicolas Sireau; Hana Ayoob; Oliver G Timmis; Kim-Hanh Le Quan Sang; Federica Genovese; Richard Imrich; Jozef Rovensky; Rangan Srinivasaraghavan; Shruthi K Bharadwaj; Ronen Spiegel; Andrea Zatkova
Journal:  Eur J Hum Genet       Date:  2015-03-25       Impact factor: 4.246

6.  Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?

Authors:  Andrew D Watt; Gabriela A N Crespi; Russell A Down; David B Ascher; Adam Gunn; Keyla A Perez; Catriona A McLean; Victor L Villemagne; Michael W Parker; Kevin J Barnham; Luke A Miles
Journal:  Acta Neuropathol       Date:  2014-05-07       Impact factor: 17.088

7.  mCSM-NA: predicting the effects of mutations on protein-nucleic acids interactions.

Authors:  Douglas E V Pires; David B Ascher
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

8.  Experimentally guided computational antibody affinity maturation with de novo docking, modelling and rational design.

Authors:  Daniel A Cannon; Lu Shan; Qun Du; Lena Shirinian; Keith W Rickert; Kim L Rosenthal; Martin Korade; Lilian E van Vlerken-Ysla; Andrew Buchanan; Tristan J Vaughan; Melissa M Damschroder; Bojana Popovic
Journal:  PLoS Comput Biol       Date:  2019-05-01       Impact factor: 4.475

9.  mCSM: predicting the effects of mutations in proteins using graph-based signatures.

Authors:  Douglas E V Pires; David B Ascher; Tom L Blundell
Journal:  Bioinformatics       Date:  2013-11-26       Impact factor: 6.937

10.  Evolution of carbapenem resistance in Acinetobacter baumannii during a prolonged infection.

Authors:  Jane Hawkey; David B Ascher; Louise M Judd; Ryan R Wick; Xenia Kostoulias; Heather Cleland; Denis W Spelman; Alex Padiglione; Anton Y Peleg; Kathryn E Holt
Journal:  Microb Genom       Date:  2018-03-16
View more
  8 in total

Review 1.  Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies.

Authors:  Rahmad Akbar; Habib Bashour; Puneet Rawat; Philippe A Robert; Eva Smorodina; Tudor-Stefan Cotet; Karine Flem-Karlsen; Robert Frank; Brij Bhushan Mehta; Mai Ha Vu; Talip Zengin; Jose Gutierrez-Marcos; Fridtjof Lund-Johansen; Jan Terje Andersen; Victor Greiff
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

2.  CSM-carbohydrate: protein-carbohydrate binding affinity prediction and docking scoring function.

Authors:  Thanh Binh Nguyen; Douglas E V Pires; David B Ascher
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 13.994

3.  DynaMut2: Assessing changes in stability and flexibility upon single and multiple point missense mutations.

Authors:  Carlos H M Rodrigues; Douglas E V Pires; David B Ascher
Journal:  Protein Sci       Date:  2020-09-11       Impact factor: 6.725

4.  mmCSM-NA: accurately predicting effects of single and multiple mutations on protein-nucleic acid binding affinity.

Authors:  Thanh Binh Nguyen; Yoochan Myung; Alex G C de Sá; Douglas E V Pires; David B Ascher
Journal:  NAR Genom Bioinform       Date:  2021-11-17

5.  Computational and Rational Design of Single-Chain Antibody against Tick-Borne Encephalitis Virus for Modifying Its Specificity.

Authors:  Ivan K Baykov; Pavel Y Desyukevich; Ekaterina E Mikhaylova; Olga M Kurchenko; Nina V Tikunova
Journal:  Viruses       Date:  2021-07-29       Impact factor: 5.048

6.  cropCSM: designing safe and potent herbicides with graph-based signatures.

Authors:  Douglas E V Pires; Keith A Stubbs; Joshua S Mylne; David B Ascher
Journal:  Brief Bioinform       Date:  2022-03-10       Impact factor: 13.994

Review 7.  Machine-designed biotherapeutics: opportunities, feasibility and advantages of deep learning in computational antibody discovery.

Authors:  Wiktoria Wilman; Sonia Wróbel; Weronika Bielska; Piotr Deszynski; Paweł Dudzic; Igor Jaszczyszyn; Jędrzej Kaniewski; Jakub Młokosiewicz; Anahita Rouyan; Tadeusz Satława; Sandeep Kumar; Victor Greiff; Konrad Krawczyk
Journal:  Brief Bioinform       Date:  2022-07-18       Impact factor: 13.994

8.  Distinguishing between PTEN clinical phenotypes through mutation analysis.

Authors:  Stephanie Portelli; Lucy Barr; Alex G C de Sá; Douglas E V Pires; David B Ascher
Journal:  Comput Struct Biotechnol J       Date:  2021-05-21       Impact factor: 7.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.